ACADIA Pharmaceuticals (formerly known as Receptor Technologies) is a biopharmaceutical company focused on the development and commercialization of medicines that address medical needs in central nervous system (CNS) disorders. Its main product is NUPLAZID that is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). The company also works on other solutions for dementia-related psychosis, Rett syndrome, negative symptoms of schizophrenia, etc.